The combination treatment of atezolizumab plus bevacizumab (anti-PD-L1 mAb plus anti-vascular drug) was shown to provide superior outcomes and has become the new standard first-line treatment for unresectable or metastatic HCC [16]. This evidence concerns the gene CD274 and hepatocellular carcinoma.